| Rabiee A, et al,95 2020 |
112 |
United States |
-
•
Mortality 22.3%
-
•
Moderate liver injury (ALT 2-5x ULN) 22.2%, severe liver injury
(ALT > 5× ULN) 12.3% -
•
Liver injury in LT recipients was associated with mortality (P = .007; OR = 6.91) and ICU admission (P = .007; OR = 7.93)
-
•
Reduction of immunosuppression during COVID-19 was not associated with mortality (P = .084)
|
| Colmenero J, et al,64 2021 (SETH registry) |
111 |
Spain |
-
•
Mortality 18%, severe COVID-19 31.5%
-
•
LT patients had an increased risk of acquiring COVID-19 but their mortality was lower than the matched general population
-
•
Mycophenolate may increase the risk of severe COVID-19 in a dose-dependent manner
|
| Kates OS, et al,96 2021 |
73 |
United States |
|
| Ravanan R, et al,97 2020 (UK National Health Service Blood and Transplant registry) |
64 |
England |
-
•
SOT recipients with SARS-CoV-2 infection had a higher all-cause mortality compared with wait-listed patients (25.8% vs 10.2%)
-
•
LT recipients had a lower SARS-CoV-2 infection rate than other SOT recipients (OR = 0.53, 95%CI 0.40–0.70)
|
| Webb GJ, et al,65 2020 (SECURE-cirrhosis and COVID-Hep) |
151 |
International registry |
-
•
Overall mortality was 18.5%
-
•
LT did not significantly increase the risk of death
-
•
Age, high creatinine level, and nonliver cancer were associated with mortality among LT recipients
|
| Belli LS, et al,66 2021 (ELITA/ELTR COVID-19 registry) |
243 |
Europe |
-
•
Mortality 20.2%, respiratory failure was the major cause of death
-
•
Older age, diabetes, and chronic kidney disease were associated with mortality
-
•
Tacrolimus use (HR = 0.55, 95%CI 0.31–0.99) had a positive independent effect on survival
|
| Polak WG, et al,98 2020 (ELITA/ELTR COVID-19 registry) |
57 SARS-CoV-2–infected LT candidates
272 SARS-CoV-2–infected LT recipients |
Europe |
|
